Oric Pharmaceuticals

ORIC

Market cap $768M

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in June:

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc.  ("Oric" or the "Company") (NASDAQ: ORIC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. (“Oric” or the “Company”) (NASDAQ: ORIC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. (“Oric” or the “Company”) (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc.  ("Oric" or the "Company") (NASDAQ: ORIC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2026 (the “Grant Date”), ORIC granted a total of 216,000 non-qualified stock options and 35,000 restricted stock units to four new non-executive employees who began their employment with ORIC in April 2026.

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. (“Oric” or the “Company”) (NASDAQ: ORIC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.